Authors and Disclosures
Andrea Giustina1, Ariel Barkan2, Albert Beckers3, Nienke Biermasz4, Beverly M. K. Biller5, Cesar Boguszewski6, Marek Bolanowski7, Vivien Bonert8, Marcello D. Bronstein9, Felipe F. Casanueva10, David Clemmons11, Annamaria Colao12, Diego Ferone13, Maria Fleseriu14, Stefano Frara1, Monica R. Gadelha15, Ezio Ghigo16, Mark Gurnell17, Anthony P. Heaney18, Ken Ho19, Adriana Ioachimescu20, Laurence Katznelson21, Fahrettin Kelestimur22, John Kopchick23, Michal Krsek24, Steven Lamberts25, Marco Losa26, Anton Luger27, Pietro Maffei28, Monica Marazuela29, Gherardo Mazziotti30, Moises Mercado31, Pietro Mortini26, Sebastian Neggers32, Alberto M. Pereira4, Stephan Petersenn33, Manel Puig-Domingo34, Roberto Salvatori35, Ilan Shimon36, Christian Strasburger37, Stylianos Tsagarakis38, A. J. van der Lely32, John Wass39, Maria Chiara Zatelli40 and Shlomo Melmed8
1Division of Endocrinology and Metabolism, San Raffaele University Hospital, Milan, Italy; 2Division of Endocrinology, University of Michigan Health System, Ann Arbor, Michigan; 3Department of Endocrinology, University of Liège, Liège, Belgium; 4Division of Endocrinology and Center for Endocrine Tumors, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands; 5Neuroendocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; 6SEMPR, Endocrine Division, Department of Internal Medicine, Federal University of Parana, Curitiba, Brazil; 7Department of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, Wroclaw, Poland; 8Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California; 9Division of Endocrinology and Metabolism, Hospital das Clinicas, University of Sao Paulo, Sao Paulo, Brazil; 10Division of Endocrinology, Santiago de Compostela University and Ciber OBN, Santiago de Compostela, Spain; 11Department of Medicine, University of North Carolina, Chapel Hill, North Carolina; 12Division of Endocrinologia, Universita' Federico II di Napoli, Naples, Italy; 13Endocrinology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy; 14Departments of Medicine and Neurological Surgery, Pituitary Center, Oregon Health & Science University, Portland, Oregon; 15Neuroendocrinology Research Center/Endocrinology Section, Medical School and Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; 16Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Turin, Turin, Italy; 17University of Cambridge & Addenbrooke's Hospital, Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, United Kingdom; 18Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California; 19The Garvan Institute of Medical Research and St. Vincent's Hospital, Sydney, Australia; 20Department of Medicine, Division of Endocrinology, Metabolism and Lipids, and Department of Neurosurgery, Emory University School of Medicine, Atlanta, Georgia; 21Departments of Medicine and Neurosurgery, Stanford University School of Medicine, Stanford, California; 22Yeditepe University, Faculty of Medicine, Istanbul, Turkey; 23Edison Biotechnology Institute and Department of Biomedical Sciences, Ohio University, Athens, Ohio; 242nd Department of Medicine, 3rd Faculty of Medicine of the Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic; 25Erasmus Medical Center, Rotterdam, The Netherlands; 26Department of Neurosurgery, San Raffaele University Health Institute Milan, Milan, Italy; 27Division of Endocrinology and Metabolism, Medical University of Vienna, Vienna, Austria; 28Department of Medicine, Padua University Hospital, Padua, Italy; 29Department of Medicine, CIBERER, Universidad Autónoma de Madrid, Madrid, Spain; 30Endocrinology Unit, Humanitas University and Humanitas Clinical and Research Center, Rozzano, Milan, Italy; 31Division of Medicine, National Autonomous University of Mexico, Experimental Endocrinology Unit, Centro Médico Nacional, Siglo XXI, IMSS, Mexico City, Mexico; 32Pituitary Center Rotterdam, Endocrinology Section, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands; 33ENDOC Center for Endocrine Tumors, Hamburg, Germany; 34Endocrinology Service, CIBER and CIBERES Germans Trias i Pujol Research Institute and Hospital, Autonomous University of Barcelona, Badalona, Spain; 35Division of Endocrinology, Diabetes, and Metabolism and Pituitary Center, Johns Hopkins School of Medicine, Baltimore, Maryland; 36Endocrine Institute, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel; 37Department of Medicine for Endocrinology, Diabetes and Nutritional Medicine, Charité Universitätsmedizin, Berlin, Germany; 38Department of Endocrinology, Diabetes and Metabolism, Evangelismos Hospital, Athens, Greece; 39Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, United Kingdom; and 40Section of Endocrinology & Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
Correspondence and Reprint Requests
Shlomo Melmed, MD, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Room 2015, Los Angeles, CA, 90048.
Author Contributions
A.G. and S.M. served as Program Coordinators of the 12th Acromegaly Consensus Conference. N.B., M.D.B., F.E.C., D.C., M.F., C.S., P.M., J.W., and A.V.D.L. served as Steering Committee Members. All authors researched data for the Conference. A.G. and S.M. wrote the initial manuscript and all authors reviewed and/or edited the manuscript before submission.
Disclosure Summary
B.M.K.B., M.B., M.D.B., V.B., D.C., M.F., A.G., A.I., A.L., M.M., S.N., S.P., C.S., I.S., R.S., and A.V.D.L. have received consulting fees from Pfizer. B.M.K.B., D.F., M.F., A.G., M.R.G., A.P..H, A.L., M.L., G.M., M.M., S.M., S.P., C.S., I.S., and M.C.Z. have received consulting fees from Novartis. D.C., D.F., M.F., A.G., A.L., M.L., G.M., S.N., S.P., and C.S. have received consulting fees from Ipsen. D.C., M.F., A.G., L.K., S.M., and C.S. have received consulting fees from Chiasma. D.C. and S.N. have received consulting fees from Crinetics. M.F. and S.M. have received consulting fees from Ionis and Ono. M.G. has received consulting fees from AstraZeneca. D.F. has received consulting fees from Bristol-Myers Squibb. M.L. has received consulting fees from Eli Lilly. S.M. has received consulting fees from Midatech. A.P.H. and R.S. have received consulting fees from Novo Nordisk. M.C.Z. has received consulting fees from Sanofi. A.P.H. has received consulting fees from Strongbridge. A.B., B.M.K.B., M.B., M.D.B., D.F., M.F., M.R.G., A.I., L.K., and R.S. have received fees for contracted research from Novartis. M.B., M.D.B., F.F.C., D.F., M.F., M.R.G., and R.S. have received fees for contracted research from Ipsen. F.F.C., M.F., A.I., P.M., S.M., and R.S. have received fees for contracted research from Pfizer. M.B., M.F., A.I., and M.P.D. have received fees for contracted research from Chiasma. M.B., K.H., and R.S. have received fees for contracted research from Novo Nordisk. M.B. and R.S. have received fees for contracted research from Strongbridge. M.B. has received fees for contracted research from HRA Pharma. M.F. has received fees for contracted research from Ionis and Ono. R.S. has received fees for contracted research from Opko Biologics. K.H. has received fees for contracted research from Versartis. C.B., M.B., M.D.B., M.G., K.H., A.L., M.M., and M.P.D. have served as members of the speakers bureau for Ipsen. C.B., M.B., M.D.B., M.G., K.H., A.L., M.M., and M.P.D. have served as members of the speakers bureau for Novartis. C.B., M.B., F.F.C., M.G., and A.L. have served as members of the speakers bureau for Pfizer. M.K. has received lecture fees from Merck, Eli Lilly, and Shire. M.R.G. has received lecture fees from Novartis. A.V.D.L. has an ownership interest in Millendo Therapeutics. A.B., N.B., A.C., S.F., E.G., F.K., J.K., S.L., P.M., A.P., S.T., and J.W. have nothing to declare.
Comments